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Abstract
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive 
tract. The majority of GISTs is located in the stomach. Only 3-5% of GISTs are located in the duodenum associated with 
an increased risk of gastrointestinal bleeding as primary manifestation. With response rates of up to 90%, but 
complications like bleeding due to tumor necrosis in 3%, imatinib mesylate dramatically altered the pre- and 
postoperative therapy for GIST patients.
Case presentation: A 58-year-old female patient presented with acute upper gastrointestinal bleeding 2 weeks after a 
giant GIST of the duodenum had been diagnosed. Neoadjuvant imatinib therapy had been initiated to achieve a tumor 
downsizing prior to surgery. During emergency laparotomy a partial duodenopancreatectomy was performed to 
achieve a complete resection of the mass. Histology revealed a high-malignancy GIST infiltrating the duodenal wall. 
Adjuvant imatinib therapy was initiated. At follow-up (19 months) the patient is still alive and healthy.
Conclusion: Giant GISTs of the duodenum are rare and - in contrast to other localizations - harbour a higher risk of 
serious bleeding as primary manifestation. Tumor necrosis and tumor bleeding are rare but typical adverse effects of 
imatinib therapy especially during treatment of high-malignancy GIST. In GIST patients with increased risk of tumor 
bleeding neoadjuvant imatinib therapy should thoroughly be performed during hospitalization. In cases of duodenal 
GIST primary surgery should be considered as treatment alternative.
Background
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal
wall. Originating in the muscular wall of the viscera pro-
liferating cells of a GIST show phenotypic similarities to
the interstitial cells of Cajal, which coordinate the peri-
staltic movements of the gastrointestinal tract [1,2].
GISTs are defined as mesenchymal, spindle-shaped
tumors, which can be distinguished from other soft tissue
tumors like leiomyomas, myoblastomas etc. by c-kit pro-
tooncogen (CD117) expression [3]. With 33-63% the
stomach is the most common site for a GIST, followed by
the small intestine (23-38%) and the colorectal localiza-
tion (5-32%). In contrast GISTs of the duodenum, as pre-
sented in this case report, are very rare.
Clinical studies demonstrated that with imatinib (STI
571, Gleevec, Novartis Pharma) objective responses can
b e  r e a c h e d  i n  m o r e  t h e n  5 0 %  o f  p a t i e n t s  w i t h  a n
advanced GIST. Unresectable locally advanced tumors,
recurrent or metastatic GISTs showed longer progres-
sion-free survival under imatinib therapy [4-6]. All in all
80-90% of the patients with GISTs showed at least a par-
tial tumor response [7]. After retrospective small-institu-
tional reports and case series the neoadjuvant use of
imatinib in GIST was first evaluated in the RTOG 0132/
ACRIN 6665 study. Eisenberg recently published first
results underlining the safety of imatinibmesylate in
treatment of GISTs [8]. In another study 3% of the
probands treated with imatinib developed complications
caused by rupture of large tumor masses which became
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necrotic unter pharmacotherapy [9]. These data corre-
spond to complication rates described in the STI 571
study [9,10]. To the best of our knowledge these compli-
cation rates only referred to common tumor localiza-
tions, but not to uncommon GIST sites as duodenum,
rectum or others [8].
We herein report a case of a patients with a giant GIST
of the duodenum. After neoadjuvant imatinib therapy
was initiated, a dramatic tumor regression led to an upper
gastrointestinal bleeding and an emergency laparotomy.
Case Report
The 58-year-old female patient was hospitalized due to
recurrent episodes of upper abdominal pain, anemia,
weight loss, fatigue and fever attacks. Under suspicion of
a duodenal perforation by a lymphoma or GIST, seen in
an ultrasound examination, the patient was transferred to
our clinic.
Physical examination of the patient with no history of
preexisting diseases revealed a palpable mass in the right
upper abdominal quadrant. Hemoglobin was 90 g/l.
Upper endoscopy revealed a large necrotic cavity in the
inferior part of the duodenum. Multiple biopsies taken
from the tumor mass confirmed the suspicion of a duode-
nal GIST. PET-CT scan showed a 9 × 9 × 15 cm tumor
mass arising from the duodenum with a maximal stan-
dard uptake value (SUV) of 15,5. The tumor had contact
to the pancreatic caput and led to compression of the
inferior caval vein and the inferior mesenterial vein. The
portal vein as well as the common hepatic artery and the
superior mesenterial artery showed no signs of infiltra-
tion or compression. Furthermore PET-CT did not reveal
any signs of metastasis. According to a neoadjuvant
approach preoperative therapy with imatinib (Gleevec,
Novartis, Basel, Switzerland), 400 mg per day, was initi-
ated immediately. Responder controll by PET-CT scan
was planned to be performed 4 weeks after initiation of
the therapy. After 2 weeks under ambulatory pharmaco-
logical therapy the patient presented in the emergency
room with an acute upper gastrointestinal bleeding. CT
confirmed a dramatic bleeding from the upper GI tract
necessitating mass blood transfusion (Fig. 1). Tumor size
decreased to 7 × 8 × 12 cm within only 2 weeks of ima-
tinib treatment. An angiographic CT showed the diffuse
tumor bleeding supplied by the gastroduodenal artery
and some branches of the superior mesenterial artery.
The diffuse bleeding forbade a coiling of the vessels. Dur-
ing the emergency laparotomy an encapsulated tumor
mass could be identified, originating from the descendent
part of the duodenum and reaching both the pancreatic
caput and the right flexure of the colon. Obviously the
giant tumor had led to a bleeding by arrosion of peripan-
creatic vessels. After ligation of the vessels supplying the
mass a partial pancreaticoduodenectomy (Traverso-
Longmire) was performed to resect the tumor (Fig. 2).
Additionally a resection of the right hemicolon was per-
formed due to tumor infiltration of the right curvature of
the colon. Continuity was reconstructed by gastroje-
junostomy (Traverso-Longmire) on the one hand and an
end-to-side-pancreaticojejunostomy on the other hand.
An ileotransversostomy was performed to reconstruct
the gastrointestinal passage.
Upon macroscopic examination the specimen showed a
partially necrotic mesenchymal mass with a diameter of 9
cm, an infiltration of the duodenal wall leading to ulcer-
ation and perforation, an infiltration of the pancreas and
two peripankreatic tumor islands (Fig. 2). There were no
signs of metastases in locoregional lymphnodes. Histo-
logical examination of the tumour tissue revealed the typ-
ical appearance of a GIST composed of cells with spindle-
shaped nuclei (Fig.3D). Immunohistochemically the
tumour cells showed an expression of Vimentin (Fig. 3C)
and CD117 (Fig. 3E), a focal expression of CD34, smooth-
muscle-actin (not shown) and a nuclear expression of the
proliferation-associated Ki-67-antigen in approximately
5-10% of the tumour cells (Fig. 3F). The tumour was neg-
ative for S-100 and Keratin (not shown).
Two days after surgery the patient was weaned and suc-
cessfully extubated. After an uneventfull recovery the
patient is alive and without any signs of tumor recur-
rence. Up to the follow-up of 19 months the patient per-
manently received an adjuvant imtinib therapy (400 mg
per day).
Discussion
GISTs are defined as mesenchymal tumors arising from
the gastrointestinal wall, mesentery, omentum or retro-
peritoneum. In contrast to leiomyo(sarko)mas GIST cells
express the c-kit proto-oncogene (CD117). Distribution
of GIST in the gastrointestinal tract was analyzed in sev-
eral studies. Tumors are mostly localized in the stomach
(33-63%), small bowel (23-38%), whereas colon, rectum
and esophagus are rare localizations. The female patient
of this case report presented with a duodenal GIST as
another rare GIST manifestation. Except for one large
study on the histopathological pattern of duodenal GIST
[11] only two studies with 8 and 15 patients respectively
are published so far [12,13] analyzing the clinic and the
outcome of duodenal GIST patients. Compared to other
tumor localizations duodenal GISTs manifestate with
tumor-associated bleeding in 90 resp. 75% compared to
54% (stomach) [14] and 28% (ileo-jejunal) [15]. In con-
trast to other localizations duodenal GISTs are thus asso-
ciated with a dramatically increased risk of an upper
intestinal bleeding [11].
Nowadays the dignity of resected tumors is classified in
risk categories that are based on size and mitotic rate
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the result that tumor size (>5 cm) and mitotic activity
(>5/50 high-power field) of the mesenchymal cells are the
most important independent prognostic factors for
tumor progression [3]. In our case postoperative exami-
nation of the specimen revealed a tumor mass of 9 × 15
cm in diameter. Ki67 was used as an immunhistochemi-
cal marker for cell proliferation. 5-10% of the tumor cells
were Ki67+. Histopathological examination revealed a
rate of 12 mitoses per 50 high power fields. Following the
above-mentioned classification our patient fulfilled all
criteria of a malignant tumor progress.
Surgical therapy of duodenal GIST depends on tumor
localization and is either partial duodenectomy, or partial
pancreaticoduodenectomy. Interestingly, a recent study
revealed that duodenal GIST cells express a different pat-
tern of immunhistochemical markers [16]. Additionally
authors showed that duodenal GIST are associated with a
more favorable prognosis compared to other tumor local-
izations. [16]. After review of recent literature the duode-
nal tumor localization in our case is thus associated with
a better prognosis, but with an increased bleeding proba-
bility. These results are in line with the authors' opinion
that primary surgery could be the safest therapeutic
option for a GIST of this localization. Beside the
increased risk of tumor bleeding, caused by the localiza-
tion, neoadjuvant imatinib therapy would additionally
l e a d  t o  a  h i g h e r  p e r c e n t a g e  o f  p a t i e n t s  w i t h  a  t u m o r
bleeding.
Without any pre- or postoperative pharmacotherapy
complete surgical resection can lead to a 5 year survival
of up to 45% [17]. The introduction of imatinib mesylate,
a tyrosine kinase inhibitor targeting KIT has provided a
much needed chemotherapeutical option for patients
Figure 1 Transversal (left) and coronal (right) CT scans of the abdomen reveal a cystic and necrotic tumor cavity 2 weeks after initiation of 
imatinib therapy.
Figure 2 Cross-section of the surgical specimen showing the tu-
mor (asterisk) infiltrating the duodenal wall (arrows).
Figure 3 A) GIST infiltrating adjacent Pancreas; asterisk = pancre-
atic glands and ducts, arrows = GIST [hematoxylin-eosin staining, 
Original magnification 50×]. B) GIST perforating into the lumen of 
the duodenum; asterisk = mucosa of the duodenum, arrowheads = ul-
ceration, arrows = GIST [hematoxylin-eosin staining, Original magnifi-
cation 50×] C) Immunohistochemical staining for Vimentin showing 
positive reaction in almost all cells (red colour) [Original magnification 
400×] D) Cells of the GIST with spindle-shaped nuclei (arrows) and ad-
mixed lymphocytes and granulocytes [hematoxylin-eosin staining, 
Original magnification 400×] E) Immunohistochemical staining for 
CD117 (c-kit) showing positive reaction in almost all cells (red colour) 
[Original magnification 400×] F) Immunohistochemical staining for Ki-
67 showing proliferation in approximately 5-10% of cells (red nuclear 
signal, arrows) [Original magnification 400×].Hecker et al. World Journal of Surgical Oncology 2010, 8:47
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with both resectable and irresectable GISTs. Despite the
noted success of imatinib surgical resection is the main
treatment modality for primary GIST of any localization.
Imatinib treatment of GISTs is a dynamic process with
the permanent risk of pharmacoresistance [4,18] and a
maximal respondance within the first 6 months of ther-
apy [4]. Nevertheless the benefit of adjuvant imatinib for
primary GIST has been underlined by several trials com-
pleted recently. As a consequence surgeons started to use
imatinib in a neoadjuvant therapy to reach tumor-down-
sizing and thus increased rates of complete tumor resec-
tion.
As mentioned above complications like tumor necrosis
and tumor bleeding occurr in 3% of patients under ima-
tinib therapy. These data are in line with results of the STI
571 study. In the prospective RTOG study Eisenberg
reports on a minimal rate of toxicity or of intraooperative
complications under neoadjuvant imatinib therapy in 30
cases [8]. Nevertheless only 1 of 30 patients with imatinib
therapy prior to surgery had a duodenal GIST [8]. It thus
remains unclear, if the high safety of imatinib can be
transferred to patients with GISTs at rare tumor localiza-
tions. Alternatively primary surgery should be seen as an
alternative therapeutic approach. In cases of duodenal
GIST primary surgery could be supported by a preopera-
tive transarterial embolization as published previously
[19].
Conclusions
(1) The review of literature reveals a higher rate of tumor
bleeding as primary tumor manifestation in cases of duo-
denal GIST. (2) Beside the rare and uncommon localiza-
t i o n  w e  d e s c r i b e  t h e  c a s e  o f  a  g i a n t  G I S T  o f  h i g h e s t
malignancy according to the classification of Fletcher et
al.(3). Imatinib led to revolutionary changes in therapy of
primary and metastatic GIST, but is associated with rapid
tumor regression, necrosis and tumor bleeding in 3%. For
the case presented a higher complication rate is to be
exspected.
In GIST patients with these localizations and thus an
increased risk of tumor bleeding neoadjuvant imatinib
therapy should thoroughly be performed during hospital-
ization. In cases of duodenal GIST primary surgery
should be considered as treatment alternative.
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